Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Aurinia Pharmaceuticals is a commercial-stage biopharmaceutical company focused on autoimmune diseases, with its lead product LUPKYNIS (voclosporin) approved for lupus nephritis treatment in the US, EU, and other markets. The company is transitioning from clinical-stage to sustainable profitability with 34% revenue growth and recently achieved positive net margins, driven by expanding LUPKYNIS adoption in nephrology and rheumatology channels. With $1.9B market cap and minimal debt, Aurinia represents a specialty pharma play on rare autoimmune indications with potential label expansion opportunities.
Aurinia generates revenue through direct sales and specialty pharmacy distribution of LUPKYNIS, a calcineurin inhibitor with orphan drug designation for lupus nephritis. The 88% gross margin reflects typical specialty pharma economics with low manufacturing costs relative to pricing power in rare disease markets. Revenue growth is driven by expanding prescriber base among nephrologists and rheumatologists, increasing patient duration on therapy, and geographic expansion. Competitive advantage stems from first-mover status in lupus nephritis oral therapy, established renal safety profile from Phase 3 AURORA trial data, and specialty sales force relationships with high-prescribing academic medical centers and community nephrology practices.
Quarterly LUPKYNIS net product revenue vs consensus estimates and sequential growth trajectory
New prescriber additions and total active prescribing physicians metrics
Clinical trial readouts for label expansion opportunities (other autoimmune indications beyond lupus nephritis)
Regulatory approvals in new geographies or expanded indications
Competitive developments in lupus nephritis treatment landscape (biosimilars, new mechanisms)
Cash burn rate and path to sustained profitability milestones
Patent cliff risk as LUPKYNIS composition of matter and method-of-use patents expire (estimated 2027-2032 depending on jurisdiction), exposing to generic competition in a relatively small market
Payer reimbursement pressure as health systems scrutinize specialty drug costs, with potential for restrictive prior authorization requirements or step therapy protocols favoring cheaper immunosuppressants
Single-product dependency creates binary risk profile until pipeline diversification or label expansion materializes
Emerging competition from novel lupus nephritis therapies including biologics (belimumab combinations) and next-generation calcineurin inhibitors with improved safety profiles
Generic immunosuppressants (mycophenolate, azathioprine) remain standard-of-care alternatives despite inferior efficacy, creating pricing pressure and market share limitations
Large pharma entry into autoimmune space with better-resourced sales forces and broader rheumatology portfolios could limit prescriber mindshare
Cash burn risk if revenue growth decelerates below operating expense base, though current 2.4% net margin and positive operating cash flow suggest near-term sustainability
Equity dilution risk if company pursues pipeline expansion through acquisitions or in-licenses requiring capital raises, though current balance sheet strength mitigates near-term needs
low - Specialty pharmaceuticals for serious autoimmune diseases exhibit minimal GDP sensitivity as treatment decisions are medically driven rather than discretionary. Lupus nephritis patients require therapy regardless of economic conditions, and insurance coverage (primarily Medicare/Medicaid and commercial plans) insulates demand from consumer spending cycles. However, severe recessions could pressure payer reimbursement rates or prior authorization requirements.
Rising rates create modest headwinds through higher discount rates applied to future cash flows in DCF valuations, particularly impactful for growth-stage biopharma with profitability inflection points. The company's $360M cash position (implied by 5.76x current ratio and minimal debt) generates higher interest income in rising rate environments, partially offsetting valuation compression. Financing costs are minimal given 0.21 debt/equity ratio.
Minimal - The company operates with strong balance sheet liquidity (5.76x current ratio) and low leverage (0.21 debt/equity). Credit conditions have limited direct impact on operations, though tighter credit could affect hospital system budgets and specialty pharmacy financing, potentially creating modest reimbursement delays.
growth - The 79% one-year return and 34% revenue growth attract growth investors focused on commercial-stage biopharma with inflection to profitability. The recent achievement of positive net margins (2.4%) and operating margins near breakeven (-2%) appeals to investors seeking de-risked growth stories with visible paths to sustained profitability. Momentum investors have driven recent performance, though 7.7% three-month decline suggests profit-taking after strong run.
high - Biotech stocks typically exhibit 1.5-2.0x market beta due to binary clinical/regulatory events, single-product concentration, and growth stock valuation sensitivity to interest rates. The 79% one-year gain followed by 7.7% recent decline illustrates characteristic volatility. Small-cap specialty pharma status ($1.9B market cap) amplifies price swings on earnings surprises or competitive news.
